Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  24.00 5.0% 504.00 112,266 16:35:27
Bid Price Offer Price High Price Low Price Open Price
502.00 504.00 508.00 502.00 502.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 154.49 -106.40 -12.06 3,575
Last Trade Time Trade Type Trade Size Trade Price Currency
16:42:14 O 5,000 504.00 GBX

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
25/9/202007:29(Chi-Med)Hutchinson China Meditech Limited2,816
31/7/201807:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201810:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 480p.
Hutchison China Meditech Limited has a 4 week average price of 470p and a 12 week average price of 390p.
The 1 year high share price is 528p while the 1 year low share price is currently 250p.
There are currently 709,274,765 shares in issue and the average daily traded volume is 78,523 shares. The market capitalisation of Hutchison China Meditech Limited is £3,574,744,815.60.
dbadvn: HaHa!! When the share price reaches £100 (which I fully expect within a few years ) I will hire a personal trainer !!
dbadvn: NoFS, I think the corporate clumsiness is well behind us (although the effects are not). Building revenue and getting to free cash flow will be the catalysts that kick the share price into action and CH knows this. I would like to see much more publicity from Astra around the Tagrisso/suraftulinib combo and a move to the UK main list + HK listing in the near future to set the company up for the long term future. Still overweight and intend to stay that way.
sportii: What disappoints and annoys is the constant feature of share price failing to maintain a healthy figure. It has lost all the momentum achieved following GA’s mega investment. Geopolitical issues too are contributing to the slide. Hoping something positive will be announced on the results day.
sportii: All longtime investors agree to the ‘very under priced‘ term. When there are no fresh buyers, however good the company is, its share price fails to achieve its real value. For reasons known only to its management, HCM continues to be listed on AIM which is hindering many institutional investors from buying HCM. Also, ‘long proposed’ HK listing is yet to happen. A migration to the main LSE market and/or listing at HK timed with some ‘positive news‘ release (eg. GA’s investment of $100 millions last month or forthcoming approval of a drug) will help to enhance its market valuation. Perhaps, we will be discussing the same on this board, in the coming year/s, like the last 2-3 years!
sportii: Its not impossible. Less than 10 years ago, share price used to be significantly low. Looking at company’s assets, its scientific team and the pipeline, present market valuation of £3.1 billion doesn’t appear too much. Undoubtedly, GA’s recent investment of 100 million USD in the company has rejuvenated the share price. These shares have always been sensitive to news updates. Going up for few days following some ‘good‘ news, later, invariably drifting down, many times to a much lower level. That trend seems to have broken this time, following GA’s involvement. There appears a sustained higher confidence in the market over last 3 weeks. If GA is poised to invest another 100 millions in the coming months, along with any successful approval/s by the authorities for one or two new therapies, is it difficult to achieve a better valuation? GLA. Do your own research etc.,
lauders: It is interesting to see that we are around the same level we are today when it comes to the share price but WAY ahead when it comes to progress: You could have bought shares in Hutchison China MediTech, or Chi-Med, listed on AIM — and on Nasdaq in the US — for 30p in the aftermath of the financial crash in 2008. When this column drew attention to the company in March they were changing hands at £22. Last week (October 2017), they went over £44. So at around £4.45 now (equivalent to £44.5 then) we have all the newsflow since on NDA submissions and new potential drugs thrown in, as well as income from Elunate, for "essentially free"! Always good to read that Anthony Hilton piece in particular NofS! I wonder where we will be at year end when the impending big news on Suru and Savo is released? I would hope well north of £5 or £50 equivalent! Can't be hard surely? PS. I added the bold date to the quote for the record. Not in the original text quoted and date taken from the date of the ES article.
lauders: Not so sure NofS. They re-wrote the terms and agreements with Lilly and that caused a huge drop in the share price at the time. I think they have bigger global ambitions and will do what is best for HCM! If any partner is brought in the terms will have to be very favourable to HCM. It will be interesting to see what happens that is for sure. Still waiting for news on the large molecule deal personally. I think that will be a game changer in some (many?) respects.
sportii: Nofs, your question in the last sentence can be properly answered only by the CEO. You may wish to email him. I think most followers of this board, share your apprehension about the poor share price. All the optimistic looking, extensive colourful research and development information remains as ‘just another news release’ to the investing community. Have we seen any improved interest in the market for these shares following recent updates by the company? (Sadly, almost none and even negative at times!). If the prospects are so bright, why aren’t the directors and existing major holders buying more and more of these shares? Due to present days’ geopolitical reason, there could be lack of interest for ADRs in the US. Apart from that, AIM listing is considered as a possible cause. I don’t know if the management has mentioned anything about the possibility of listing on the main LSE market. If at all, moving to the main LSE isn’t a feasible option, why not an early decision about HK listing?
its the oxman: Always frustrating when share price falls but we need to keep in mind it is often what institutions demand and HCMs prospects will be stronger if it stays well financed. It was also done from a reasonable position of share price strength. For me as long as co keeps delivering and drug progress continues , value will keep building so all is good and this will be a small blip.
thornyone: The HCM share price has been behaving predictably. From January 2018 the news has been solidly negative and this is reflected in the price dropping from $40 to $17 in waves. However, more than a reversal of these numbers is possible as soon as a globally exciting test result is received. Everything else, such as publicity about pipelines and listings is just a distracting sideshow.
Hutchison China Meditech share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200927 05:00:24